Retatrutide's Breakthrough Obesity Results
Lilly's Retatrutide Demonstrates Superior Weight Loss, Reduced CV Risk in Pivotal Phase 3 Trials
Anonymous
Key Points
1
Insiders sold about $18.6 million worth of Eli Lilly shares in the last three months, signaling notable insider trading activity ahead of retatrutide news.
2
In TRIUMPH-2, weight losses averaged 29.8 lbs (4 mg), 45.4 lbs (9 mg), and 49.6 lbs (12 mg) over 80 weeks versus 9.3 lbs with placebo; in TRIUMPH-3, losses averaged 52.7 lbs (9 mg) and 55.8 lbs (12 mg) at 80 weeks.
3
Retatrutide produced A1C reductions of up to 1.6 percentage points in TRIUMPH-3 over 80 weeks.
4
Beyond weight loss, retatrutide reduced cardiovascular risk factors in TRIUMPH-3, including triglycerides, non-HDL cholesterol, waist circumference, and high-sensitivity C-reactive protein.
5
The pooled MACE-5 hazard ratio for retatrutide was 0.82 (95% CI: 0.55 to 1.22), with major adverse cardiovascular events occurring less frequently than anticipated.
Eli Lilly's experimental obesity drug retatrutide has cleared two major Phase 3 trials, with patients losing up to 55.8 pounds over 80 weeks — more than five times the weight lost on a placebo. Nasdaq reported that Lilly now plans to file for FDA approval in the first quarter of 2027.
Retatrutide targets three hormone receptors at once — GIP, GLP-1, and glucagon — making it a so-called "triple agonist." BioSpace called it Lilly's "next-generation obesity therapy," and the new data puts it on track to become one of the most powerful weight-loss drugs ever approved.
TRIUMPH-2 and TRIUMPH-3 Trial Results by the Numbers
In TRIUMPH-2, patients with obesity and type 2 diabetes lost an average of 29.8 lbs on the lowest dose (4 mg), 45.4 lbs on the middle dose (9 mg), and 49.6 lbs on the highest dose (12 mg). The placebo group lost just 9.3 lbs. All results were measured at 80 weeks, according to Nasdaq.
TRIUMPH-3 tested patients with severe obesity and heart disease. Results were even stronger. The 9 mg dose produced average losses of 52.7 lbs, while the 12 mg dose led to 55.8 lbs lost. Blood sugar control also improved. Benzinga noted that A1C levels dropped by up to 1.6 percentage points in TRIUMPH-3 — a meaningful gain for people managing diabetes.
Heart Health Benefits Go Beyond Weight Loss
Retatrutide didn't just shrink waistlines. In TRIUMPH-3, the drug also cut triglycerides, non-HDL cholesterol, waist circumference, and high-sensitivity C-reactive protein — all markers tied to heart disease risk. Benzinga highlighted these cardiovascular benefits as a key part of the drug's appeal for patients who already have heart conditions.
On major heart events, the pooled data showed a hazard ratio of 0.82, with a 95% confidence interval of 0.55 to 1.22. In plain terms, patients on retatrutide had fewer serious heart events than expected, though the result wasn't statistically definitive. Lilly will need a dedicated cardiovascular outcomes trial to confirm that benefit.
Side Effects Were Common but Manageable
The most reported side effects were gastrointestinal — nausea, vomiting, and diarrhea. These are common with GLP-1 class drugs. Pharmaphorum noted that discontinuation rates across both trials remained manageable, meaning most patients were able to stay on the drug through the full 80-week period.
Lilly is also studying retatrutide for conditions beyond obesity. Potential future indications include knee osteoarthritis pain and obstructive sleep apnea, according to Nasdaq. That broader pipeline could significantly expand the drug's commercial reach if approved across multiple uses.
FDA Filing Set for Early 2027 as Investors Watch Closely
Lilly plans to submit a Biologics License Application — the formal FDA approval request — in Q1 2027, Pharmaphorum reported. The company is also pursuing regulatory filings in other countries. If approved on schedule, retatrutide could reach U.S. patients by late 2027 or early 2028.
Investor attention is already high. Stocktwits noted the strong market reaction to the trial results. Separately, insiders sold about $18.6 million worth of Lilly shares in the past three months — a notable signal ahead of major trial news. Lilly's obesity portfolio, which already includes tirzepatide (Zepbound), is shaping up as one of the most valuable in the pharmaceutical industry.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
29
Articles
47
Reach
76
A
AnonymousAuthor